A 52-year-old woman with endometrial carcinoma has a FIGO 2023 molecular classification showing microsatellite instability-high (MSI-H) status. This molecular subgroup is associated with which prognosis and treatment implication?
- A Worst prognosis; requires aggressive platinum-based chemotherapy
- B Best prognosis regardless of histological grade
- C Intermediate prognosis; responds to immune checkpoint inhibitors ✓
- D Associated with TP53 mutation and serous histology
Correct answer: C. Intermediate prognosis; responds to immune checkpoint inhibitors
Explanation
FIGO 2023 endometrial cancer molecular classification includes: POLE-ultramutated (best prognosis), MMR-deficient/MSI-H (intermediate prognosis, responds to immune checkpoint inhibitors like pembrolizumab), NSMP (no specific molecular profile, intermediate), and p53-abnormal (TP53-mutant, worst prognosis, serous-like). MSI-H endometrial cancer is treated with pembrolizumab in recurrent/advanced disease, with FDA approval for dMMR/MSI-H tumors.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.